

**Lin v. MetLife**

**07 civ. 3218**

**EXHIBIT O**



MOUNT SINAI  
SCHOOL OF  
MEDICINE

Louis M. Aledort, M.D., M.A.C.P.

The Derald H. Ruttenberg  
Treatment Center

Mount Sinai School of Medicine  
1190 Fifth Avenue, Box 1006  
New York, NY 10029-6574

Tel.: 212.860.0205

Fax: 212.987.3326

E-mail: louis.aledort@mssm.edu

March 12, 2008

Mr. Ted Trief  
Trief & Olk  
150 East 58<sup>th</sup> Street, 34<sup>th</sup> Floor  
New York, NY 10155

Re: Bang Lin

Dear Mr. Trief,

I am the Mary Weinfeld Professor of Clinical Research in Hemophilia, a chaired faculty at the Mount Sinai School of Medicine in New York City. I am licensed to practice medicine in the State of New York and am board-certified in Internal Medicine and Hematology. I was actively involved in the research of the epidemiology of HIV and Hepatitis B and C in hemophilia and transfusion recipients supported by the CDC and the National Institutes of Health. I have reviewed the medical records of Bang Lin from his treating physician, Dr. Kam, as well as the deposition transcript of the Dr. Kam.

Commencing in September 5, 1998, Mr. Lin treated with Dr. Kam for Hepatitis B. Hepatitis B is common among the Asian population and is often vertically transmitted from mother to child. A large number of Asians infected with Hepatitis B spontaneously recover from the condition, and a large number are treated successfully.

Although the etiology of Mr. Lin's Hepatitis B is unclear, his diagnosis is. He began treatment with Dr. Kam. Dr. Kam prescribed interferon therapy for Mr. Lin beginning in September 1998. Interferon was the accepted treatment for Hepatitis B at that time. The interferon treatment ended on about February 6, 1999. Dr. Kam continued to monitor Mr. Lin through regular lab testing until 2005. Mr. Lin expired on August 11, 2006 as a result of contracting stomach cancer. His death was completely unrelated to his diagnosis of Hepatitis B.

Mr. Lin's lab test results over the period of time that he was treated and monitored by Dr. Kam verify that he was, indeed, as Dr. Kam informed the patient, successfully treated and cured of Hepatitis B. After being treated with interferon, on November 14, 1998, Mr. Lin showed a conversion of Hepatitis B antigen from positive to negative, demonstrating that his condition had been successfully treated and he no longer had an active infection. This is verified in the lab results and handwritten medical records from Dr. Kam on that date.



Significantly, after treatment, Mr. Lin's lab markers showed a consistent trend of normal liver function and negative HBV DNA results, indicating that his Hepatitis B was no longer active and thus had no impact on his longevity or survival. The HBV DNA test results, such as in February 19, 2003 and February 7, 2004, although minimally elevated, are within the realm of testing error, and because of the low concentration and lack of clinical significance, are to be considered as negative.

Additionally, ultrasounds in 1998 and 2004, as well as a normal alpha feto protein test on September 5, 1998, and consistently normal blood counts, indicate that Mr. Lin was not suffering from cirrhosis or liver cancer during the period of his continued follow-up.

I concur with the course of treatment prescribed by Dr. Kam and his subsequent conclusion, as he stated to the patient, that he was successfully treated and cured. Mr. Lin's clinical condition, response to therapy, and normal lab results (including minimally elevated laboratory test results within the range of lab error), indicated that he was successfully treated and needed no further intervention. Mr. Lin's prognosis with respect to his longevity was not reduced by his successful treatment for Hepatitis B.

I hold the above opinions to a reasonable degree of medical certainty.

Sincerely,




Louis M. Aledort, MD, MACP

LMA/nds

I hereby attest that the facts and opinions contained in my narrative report dated March 12, 2008 regarding Bang Lin are my own and are held to a reasonable degree of medical certainty.

Signed under the pains and penalties of perjury on this 29 day of April 2008.

  
\_\_\_\_\_  
Louis Aledort, M.D.

## Curriculum Vitae

LOUIS M. ALEDORT, M.D.

**Date of Birth:** December 28, 1934

**Marital Status:** married, 2 children

**Home Address:**

300 Central Park West, #3H  
New York, New York 10024

**Office Address:**

Louis M. Aledort, MD  
The Mary Weinfeld Professor of Clinical Research in Hemophilia  
Mount Sinai School of Medicine  
One Gustave L. Levy Place, Box 1006  
New York, NY 10029-6574  
Tel.: 212.241.7971  
Fax: 212.987.3326  
[louis.aledort@mssm.edu](mailto:louis.aledort@mssm.edu)

**Education & Training:**

Queens College of the City of New York, Bachelor of Science, Chemistry	1951-1955
Albert Einstein College of Medicine, Bronx, New York Doctor of Medicine	1955-1959
Intern, Internal Medicine, University of Virginia Hospital	1959-1960
Resident, Internal Medicine, University of Virginia	1960-1961
Associate Resident in Internal Medicine, Strong Memorial Hospital, Rochester, New York	1963-1964
Hematology Fellowship, Strong Memorial Hospital, Rochester, New York	1964-1966

**Licensure:**

Licensed to practice medicine in the State of New York  
New York State License #90221 Date issue: January 1, 1966  
Certification, Board of Hematology #24532, 1972  
Certification, Board of Internal Medicine #24532, 1966

**Other Academic Positions:**



1961-1963 Raphael	NIAMD, Bethesda, Maryland	Clinical Associate with Dr. Shulman, Hematology Division (USPHS Sr. Asst. Surgeon)
1964-1966	University of Rochester Rochester, New York	Instructor in Medicine Medical School, Fellow in Hematology, Associate Physician
1966-1967	The Mount Sinai Hospital, New York, New York	Research Assistant in Hematology
1966-1967	Mount Sinai School of Medicine New York, New York	Associate in Medicine
1967-1973	Mount Sinai School of Medicine New York, New York	Assistant Professor in Medicine
1967-1973	Mount Sinai School of Medicine New York, New York	Assistant Attending in Medicine
1973-1979	Mount Sinai School of Medicine New York, New York	Associate Professor in Medicine
1973-1979	Mount Sinai School of Medicine New York, New York	Associate Attending in Medicine
1975-1988	Mount Sinai School of Medicine New York, New York	Vice Chairman, Dept. of Medicine
1979	Mount Sinai School of Medicine New York, New York	Professor in Medicine
1979	Mount Sinai School of Medicine New York, New York	Attending in Medicine
1979	Cornell University Medical College New York, New York	Adjunct Professor in Medicine
1988-1994	Mount Sinai School of Medicine New York, New York	Dean for Faculty & Hospital Affairs
1993-present	Mount Sinai School of Medicine New York, New York	The Mary Weinfeld Professor of Clinical Research in Hemophilia
1999-present	New School University	Scientist-in-Residence

**Major Positions:**

1966-1978	Director, Coagulation Laboratory, The Mount Sinai Hospital, New York
1966-1976	Director, Student Health, Mount Sinai School of Medicine, New York
1969-1983	Medical Director, National Hemophilia Foundation
1970-1980	Medical Secretary, World Federation of Hemophilia
1972-1997	Director of International Hemophilia Training Center at Mount Sinai School of Medicine, New York
1974-1979	Executive Secretary, Policy Board, Persantine Aspirin Refraction Study
1975-1983	American Society of Hematology, Public Information Committee



1975-1985	Advisory Panel, House, Ways and Means Committee on National Health Insurance
1975-1983	Permanent Seat, American Blood Commission
1975-1977	Vice President, American Blood Commission
1975-1980	Panel on Review of Blood and Blood Derivatives, FDA panel member
1975-1980	Executive Committee, American Blood Commission
1977-1980	Medical Advisory Board, American National Red Cross
1978-1979	Secretary, American Blood Commission
1978-1983	Plasma and Plasma Products Committee, American Blood Commission
1980-1986	Blood Consultant, World Health Organization
1980-1984	Executive Secretary, Policy Board, Persantine Aspirin Reinfraction Study II
1982-1986	Clinical Practice Committee, American Society of Hematology
1983-1993	Chairman, Committee on Practice, American College of Physicians
1983-	Member, Board of Directors, Scientific Advisory Committee, Vice President, Irvington Institute for Immunological Research
1984-1986	Chairman, International Hemophilia Training Centers of the World Federation of Hemophilia
1986-1988	Vice President, Faculty Practice Associates, Mount Sinai School of Medicine
1986-	Co-Chairman, International Congress on Thrombosis and Hemostasis, Subcommittee on Factor VIII & IX
1986-	Member, International Congress on Thrombosis and Hemostasis, Subcommittee on von Willebrand's Disease
1987-1993	Chairman, Committee of Practice, American Society of Hematology
1987-1988	Public Education Committee, American Society of Hematology
1988-1993	Member, Committee on Public Information and Governmental Affairs, American Society of Hematology
1990-1993	Member, Committee on Practice, American College of Physicians
1993-	Chairman, Fellowship Committee, Irvington Institute for Immunological Research
1994-	Member, Education Committee, American Society of Hematology
1994-1998	Medical and Scientific Advisory Committee, World Federation of Hemophilia
1994-	Editorial Advisory Board, Hemophilia
1995-	Member, Advisory Board, Maternal and Child Health Bureau, HHS
1996-	Scientific Advisor, American National Red Cross
1997-	Member, Professional Advisory Committee, Visiting Nurse Service of New York
1997-	Member, Medical and High Tech Advisory Committee, Visiting Nurse Service of New York
1997-	Member, Scientific Advisory Committee, Nabi
1997-	Member, Scientific Advisory Committee, Novo Nordisk Pharmaceuticals, Inc.
1995-2000	Member, Borough of Tenaflly (NJ) Department of Health
1998-2000	President, Borough of Tenaflly (NJ) Department of Health
2000-present	Councilor, American College of Physicians-American Society of Internal Medicine, Downstate I Manhattan North Council
2000-present	District President, American College of Physicians-American Society of Internal Medicine, Downstate I Manhattan North
2003-present	Member, Editorial Board, <i>Current Hematology Reports</i>
2003-present	Member, Board of Governors, Eugene Lang College of New School University
2003-2006	Member, Editorial Board, <i>American Journal of Hematology</i>
2007-present	Associate Editor, <i>Haemophilia</i>

**Professional Activities:**

1969-1970	President, Albert Einstein College of Medicine Alumni
1970-1972	Alumni Council, Yeshiva University
1972-1983	Testify before: House, Ways and Means Committee Senate and House Health Subcommittee Foreign and Interstate Commerce Committee
1972	Hemophilia Liaison to WHO



1972-1973	Task Force, NHLI - Coagulation
1972-1973	Task Force on Medically Important Problems, NIGMS
1974-1975	Ad Hoc Committee for Establishment of American Blood Commission, HEW
1974-1975	Task Force on Synthesis of Factor VIII, NHLI
1974-1975	Task Force on Factor VIII Inhibitors, NHL
1974-1975	Task Force on Factor IX, FDA/NHLI
1974-1975	Task Force on Animal Models, National Academy of Sciences, NRC, ILAR
1974-1975	Coordinator, Workshop on VIII-Carrier Detection, NHLI
1974-1978	Chairman, Committee on International Conservation of Blood Resources, WFH
1974-1975	Factor VIII Subcommittee of the International Society on Thrombosis and Hemostasis
1975-1976	Coordinator, Hemophilia Education Program, NHLI/OPCE
1976-1976	New York Advisory Committee, ACP-Governor Downstate Region 1
1976-1976	Chairman, Workshop on Complications of Hemophilia, NHLI, FDA, NHF
1976-1976	Advisory Committee, Public Law #94-63, HSA
1976-1976	Advisory Committee, Implementation of Public Law #94-31, NHLI
1976-1980	Standing Committee on Blood and Blood Component Utilization, ABC
1976-1977	Hematology Consultant, PSRO
1976-1976	Member, Technical Advisory Board of the Booz-Allen Hemophilia Study
1976-1977	Member, Advisory Board of the HSA Hemophilia Program
1979-1981	Search Committee, University of Rochester, Hemophilia Center Medical Director
1979-1981	Search Committee, NHF Executive Director
1979-1988	Editorial Advisory Board, Primary Cardiology
1979-1983	US/USSR Exchange Program - Problem Area 6, NHLBI
1981-1984	Member, Genetic Disease Review and Advisory Committee of the HSA
1981-1985	Member, Blood Diseases and Resources Advisory Committee of the NHLBI
1981-1986	Member, Expert Advisory Panel on Human Blood Products and Related Substances
1982-1992	Editorial Advisory Board, Hospital Practice
1982-1986	Secretary of Health Task Force on Auto Immune Deficiency Syndrome (AIDS)
1983-1986	Editorial Board, AIDS Research
1983-	NHLBI Task Force on Auto Immune Deficiency Syndrome (AIDS)
1984-1987	Member, ICTH Subcommittee on Factor VIII and von Willebrand Factor
1985-1990	Member, Committee on Health and Public Policy
1986-1990	Working Group, Medical, Social and Health Policy Implications of Screening Tests for Anti-HIV, AIDS Institute
1987-	Subcommittee on vWF, ICTH
1987-	Subcommittee on Factor VIII and IX, ICTH
1987-	Consultant Field Reader, Office of Orphan Products Development, Department of Health and Human Services
1987-	Member, Local Arrangements Committee of the American College of Physicians.
1989-	Member, Legislation Committee of the American Society of Internal Medicine
1994-	Member, Subcommittee on Factor VIII and IX, International Society on Thrombosis and Hemostasis
1994-	Member, Medical Advisory Board, World Federation of Hemophilia
1994-	Data Monitoring Committees:
	PARIS Study
	Recombinant VIII (Chairman)
	PCR for Biologics
	Activated Prothrombin Complex Materials for the Treatment of Antibodies
	HIV Vaccine and Viral Titres
	Factor IX Products and Viral Safety in PUPs
1996-	Member, Internal Advisory Committee, Gene Therapy Hemophilia B
2001	Frederick Stohlman Jr. MD Visiting Professor, St. Elizabeth's Medical Center of Boston
2001-present	Member, Program Coordinating Committee, American College of Physicians
2002-present	Member, Editorial Board, <i>Thrombosis Journal</i>
2002-present	Member, Editorial Board, <i>Current Hematology Reports</i>



**Professional Membership:**

1968- American Society of Hematology  
1968- New York Society for the Study of Blood  
1968- International Society of Hematology  
1968- American Physiological Society  
1970- Fellow of the American College of Physicians, #00017342  
1971- Council on Thrombosis, American Heart Association  
1976- American Association for the Advancement of Science

**Review for Following Journals:**

Proceedings of the Society for Experimental Biology and Medicine  
Blood  
Circulation  
Medical Letter  
Journal of Laboratory and Clinical Medicine  
Thrombosis Research  
Annals of Internal Medicine  
American Journal of Cardiology  
New England Journal of Medicine  
American Journal of Medical Genetics  
Thrombosis and Hemostasis  
Mount Sinai Journal  
American Dental Assistants Association  
American Journal of Medicine  
Journal of Infectious Diseases  
Haemophilia

**Awards and Honors:**

1983 Alpha Therapeutic Award  
1984 Mount Sinai School of Medicine, Department of Medicine Service Award  
1984 NHF Murray Thelin Science Award  
1986 Festschrift, presented by NHF, proclaimed "Lou Aledort Day"  
1990 Mount Sinai Medical Center, Dept. of Nursing Life Time Achievement Award  
1991 Solomon Berson Award  
1998 Tribute Symposium: National, Cultural, and Economic Considerations Affecting Diagnostic and Treatment Practices in Hemophilia Throughout the Americas: A Pan-Caribbean Conference; San Juan, Puerto Rico  
2004 Mastership, American College of Physicians  
2005 Laureate Award, American College of Physicians, NY Chapter

**Academic Activities:**

Transfusion Committee  
Patient Care Committee  
Internship Committee  
Semi-Private Committee  
Attendings Committee  
House Staff Integration Committee  
Medical Service Plan Advisory Council  
Academic Council Committee on Promotions (Medical Students)  
Unit Management  
Search Committee for Spinal Cord Injury Center (Bronx VA)  
VA Dean's Committee  
Academic Council Committee on Promotions  
Chart Review Committee  
House Staff Evaluation Committee

Ward Billing Committee  
Private Ambulatory Care Model  
Patient Scheduling Committee  
Nurse Retention and Recruitment Task Force  
Ad Hoc Subcommittee to Review Use of 10% Special Fund  
Ad Hoc Committee on Research and Educational Resources  
Ad Hoc Committee to Review Anesthesiology Residency Program  
Surveillance Committee  
Clinical Standards Committee  
Clinical Advisory Committee  
Code of Behavior Committee  
Teaching Committee  
Moonlighting Committee  
Executive Committee of the Association of the Attending Staff  
Evidence-based teaching



## Bibliography

1. Millichap JG, Aledort LM, Madsen JA. A critical evaluation of therapy of febrile seizures. *J Pediatr* 1960; 56: 3: 364-368.
2. Millichap JG, Madsen JA, Aledort LM. Studies in febrile seizures: V. clinical and electroencephalographic study in unselected patients. *Neurol* 1960; 10: 7:643-653.
3. Shulman NR, Marder VJ, Aledort LM, Hiller MC. Complement-fixing isoantibodies against antigens common to platelets and leukocytes. *Trans Assoc Am Physic* 1962; 75: 89-98.
4. Shulman NR, Marder VJ, Aledort LM, Hiller MC. Isoantibodies against platelets and leukocytes. *Proc Soc Blood Transf* 1964; 439-447.
5. Moss AJ, Aledort LM. Use of Edrophonium (Tensilon) in the Evaluation of Supraventricular Tachycardias. *Am J Cardiol* 1966; 17: 58-62.
6. Aledort LM, Hodges M, Brown JA. Irreversible Renal Failure Due to Malignant Lymphoma. *Ann Intern Med* 1966; 65: 1: 117-121.
7. Aledort LM, Weed RI, Troup SB. Ionic Effects on Firefly Bioluminescence Assay of Red Blood Cell ATP. *Analyt Biochem* 1966; 17: 2: 268-277.
8. Weiss HJ, Aledort LM. Impaired platelet/connective-tissue reaction in man after aspirin ingestion. *Lancet* 1967; 495-497.
9. Aledort LM, Lord GP. Idiopathic Pulmonary Hemosiderosis: Severe Anemia Without Hemoptysis - One Year Follow-Up of Pulmonary Function. *Arch Intern Med* 1967; 120: 220-223.
10. Aledort LM, Troup SB, Weed RI. Inhibition of Sulfhydryl-Dependent Platelet Functions by Penetrating and Non-Penetrating Analogues of Parachloromercuribenzenes. *Blood* 1968; 31: 4: 471-479.
11. Aledort LM, Niemetz J. Dissociation of Platelet Aggregation from Clot Retraction, Potassium Loss, and Adenosine Triphosphatase Activity. *Proc Soc Exp Biol Med* 1968; 128:658-661.
12. Weiss HJ, Aledort LM, Kochwa S. The Effect of Salicylates on the Hemostatic Properties of Platelets in Man. *J Clin Invest* 1968; 47: 9: 2169-2180.
13. Aledort LM, Hirsch C, Udkow M, Puszkun E. Effect of Anticoagulants on Calcium and Magnesium Content of Human Platelets. *Transfusion* 1969; 9: 4: 212-213.
14. Puszkun E, Aledort LM, Puszkun S. Human Platelets: Amino Acid Synthesis. *Proc Soc Exp Biol Med* 1969; 131: 957-959.
15. Puszkun E, Aledort L, Puszkun S. The labeling of dicarboxylic amino acids and their amides by glucose and acetate in human platelets. *J Lab Clin Med* 1970; 75: 2: 234-243.
16. Puszkun E, Puszkun S, Aledort LM. Colchicine-binding Protein from Human Platelets and Its Effect on Muscle Myosin and Platelet Myosin-like Thrombosthenin-M. *J Biol Chem* 1970; 246: 2:271-276.
17. Aledort LM. The Management of Hemophilia: A Perspective. *Drug Ther* 1971; 1: 3: 55-59.
18. Aledort LM, Gilbert HS, Puszkun E. Patterns of Endogenous Platelet Serotonin Release. *Transfusion* 1971; 11: 5: 266-269.



19. Puszkin E, Gutfreund D, Aledort LM. Hemostatic Abnormalities in Heroin Addicts. *Transfusion* 1972; 12: 1: 9-11.
20. Goldman BA, Aledort LA [sic]. Essential Athrombia: A Family Study. *Ann Intern Med* 1972; 76: 2 :269-273.
21. Litwak RS, Jurado RA, Lukban SB, Mitchell BA, Kahn M, Berger S, Estioko MR, Aledort L. Perfusion without donor blood. *J Thorac Cardiovasc Surg* 1972; 64: 5: 714-728.
22. Burrows L, Haimov M, Aledort L, Leiter E, Nirmul G, Shanzer H, Taub R, Glabman S. The Platelet in the Obliterate Vascular Rejection Phenomenon. *Transplant Proc* 1973; 5: 1: 157-160.
23. Aledort LM, Puszkin S, Puszkin E, Hanson J, Katz AM. Control of Platelet Contraction. *Ser Haemat* 1973; 6: 3: 410-417.
24. Hanson JP, Repke DI, Katz AM, Aledort LM. Calcium ion control of platelet thrombosthenin ATPase activity. *Biochim Biophys Acta* 1973; 314: 382-389.
25. Berger S, Aledort LM, Gilbert HS, Hanson JP, Wasserman LR. Abnormalities of Platelet Function in Patients with Polycythemia Vera. *Cancer Res* 1973; 33: 2683-2687.
26. Puszkin S, Puszkin E, Katz AM, Aledort LM. Control of platelet actomyosin activity: effect of ADP on superprecipitation and ATPase activity of human platelet actomyosin. *Biochim Biophys Acta* 1974; 347: 102-112.
27. Aledort LM. Blood fractions for hæmophilia. *Lancet* 1974; 2: 1452.
28. Hearing before the Subcommittee on Health of the Committee on Labor and Public Welfare, United States Senate, Ninety-Third Congress, First Session on S.1326 (Hemophilia Act of 1973) to amend the Public Health Service Act to provide for programs for the diagnosis and treatment of hemophilia, November 15, 1973 (Testimony of Louis M. Aledort, MD) 1974, 22-25.
29. Aledort LM, Gilbert MS, Rapaport SI. Introduction: Recent Advances in Hemophilia. *Ann NY Acad Sci* 1975; 240: 5-6.
30. Walsh PN, Rizza CR, Evans BE, Aledort LM. The therapeutic role of epsilon aminocaproic acid (EACA) for dental extractions in hemophiliacs. *Ann NY Acad Sci* 1975; 240: 267-276.
31. Aledort LM (ed). Recent Advances in Hemophilia. *Ann NY Acad Sci* 1975; 240: 1-426.
32. Tamari Y, Aledort L, Puszkin E, Degnan TJ, Wagner N, Kaplitt MJ, Pierce EC II. Functional Changes in Platelets During Extracorporeal Circulation. *Ann Thorac Surg* 1975; 19: 6: 639-647.
33. Benis AM, Nossel HL, Aledort LM, Koffsky RM, Stevenson JF, Leonard EF, Shiang H, Litwak RS. Extracorporeal Model for Study of Factors Affecting Thrombus Formation. *Thrombos Diathes Haemorrh* 1975; 34: 1: 127-144.
34. Aledort LM. Animal research and the shrinking dollar. *J Lab Clin Med* 1975; 86: 6: 899-900.
35. Gorlin R, Aledort LM. Stop the Clot, Stop the Infarction. *Prim Cardiol* 1975; 1: 3: 4.
36. Kasper CK, Aledort LM, Counts RB, Edson JR, Fratantoni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Shulman NR, van Eys J.



- A More Uniform Measurement of Factor VIII Inhibitors. *Thrombos Diathes Haemorrh* 1975; 34: 869-872.
37. Aledort LM. Can a National All Voluntary Blood Transfusion Service by Adequate Blood Component Therapy Cover Actual and Future Needs of AHF? *Vox Sang* 1976; 31: 296-297.
  38. Patel I, Aledort L, Puszkin EG. Amino Acid Metabolism of Platelets in Leukemia. *Cancer Res* 1976; 36: 1263-1266.
  39. Aledort LM. Platelets and Thromboembolism. *Thromb Plate Anticoag* 1976; 2: 156-165.
  40. Aledort LM. Anticoagulant Drugs: When to Use - and How. *Primary Cardiol* 1976 ;2: 38-40.
  41. Aledort LM. Anti-Platelet Drugs: Newest in Anticoagulant Therapy. *Primary Cardiol* 1976; 2: 34-37.
  42. Supplemental Hearing before the Subcommittee on Health and the Environment of the Committee on Interstate and Foreign Commerce, House of Representatives, Ninety-Fourth Congress, Second Session on H.R. 12937, H.R. 14309, and H.R. 14822 (identical bills), bills to establish a national system of maternal and child health care, and H.R. 14497, a bill to establish a national health insurance system for maternal and child health care, September 13, 1976 (Maternal and Child Health Care Act, 1976) (Testimony of Louis M. Aledort, MD) 1976; 250-256.
  43. Ambrose JA, Aledort LM. Human model for the study of abnormal platelet function in atherosclerotic heart disease. *Am J Cardiol* 1976; 38: 667-668.
  44. Aledort LM, Grupenhoff JT. Legislative Considerations for Studies with Animal Models. *Animal Models of Thrombosis and Hemorrhagic Diseases*, DHEW Publication No. (NIH) 76-982. NIH 1976; 159-165.
  45. Klein HG, Aledort LM, Bouma BN, Hoyer LW, Zimmerman TS, DeMets DL. A co-operative study for the detection of the carrier state of classic hemophilia. *N Engl J Med* 1977; 296: 959-962.
  46. Aledort LM. Factor IX and thrombosis. *Scand J Haematol* 1977; 30(suppl): 40-42.
  47. Aledort LM. Home Care - An International Challenge. *Scand J Haematol* 1977; 30(suppl): 55.
  48. Aledort LM. World Use of Blood Products for Hemophilia. *Scand J Haematol* 1977;30(suppl): 56-57.
  49. Aledort LM. Methods of Care, Products Available, Complications of Therapy. *Mt. Sinai J Med* 1977; 44: 3: 332-338.
  50. Joint Hearing before the Subcommittee on Health Committee on Ways and Means and the Subcommittee on Health and the Environment Committee on Interstate and Foreign Commerce, U.S. House of Representatives, Ninety-Fifth Congress, First Session on H.R. 6575 Hospital Cost Containment Act of 1977, May 13, 1977 (Testimony of Louis M. Aledort, MD) 1977, 1074-1077.
  51. Aledort LM: Hematologic Management and Surgery in Hemophilia. *Mt. Sinai J Med* 1977; 44: 3: 371-373.
  52. Gilbert MS, Aledort LM (eds): Comprehensive care in hemophilia: a team approach. *Mt. Sinai J Med* 1977; 44: 3: 313-479.



53. Aledort LM: Epilogue. Mt. Sinai J Med 1977; 44: 3: 477-479.
54. Aledort LM: Anticoagulation with Coumarin Drugs. Primary Cardiol 1977; 3: 34-37.
55. Akhmeteli MA, Aledort LM, Alexanians S, Bulanov AG, Elston RC, Ginter EK, Goussev A, Graham JB, Hermans J, Larrieu MJ, Lothe F, McLaren AD, Manucci [sic] PM, Prentice CRM, Veltkamp JJ. Methods for the detection of haemophilia carriers: a Memorandum. Bulletin WHO 1977; 55: 6: 675-702.
56. Aledort LM. When to Anticoagulate with Heparin. Primary Cardiol 1977; 3: 20-23.
57. Patel IP, Ambinder E, Holland JF, Aledort LM. In Vitro and In Vivo Comparison of Single Donor Platelets and Multiple-Donor Pooled Platelets Transfusions in Leukemic Patients. Transfusions 1978; 18: 1: 118-121.
58. Hearings before the Subcommittee on Health of the Committee on Ways and Means, House of Representatives, Ninety-Fifth Congress, Second Session, June 19, 22, 1978 (Amendments to the Medicare Program) (Testimony of Louis M. Aledort, MD) 1978; 359-360.
59. Evans BE, Aledort LM. Hemophilia and dental treatment. JADA 1978; 96: 827-834.
60. Gendelman S, Aledort L, Hollin S. Intracranial Meningioma in Factor IX Deficiency. JAMA 1978; 239: 8: 748-749.
61. Evans BE, Aledort LM. Inhibition of ejaculation due to epsilon aminocaproic acid. N Engl J Med (letter) 1978; 298: 3 :166-167.
62. Eyster ME, Gill FM, Blatt PM, Hilgartner MW, Ballard JO, Kinney TR, and the Hemophilia Study Group. Central Nervous System Bleeding in Hemophiliacs. Blood 1978; 51: 6: 1179-1188.
63. Lusher JM, McMillan CW, and the Hemophilia Study Group. Severe Factor VIII and Factor IX Deficiency in Females. Am J Med 1978; 65: 637-648.
64. Evans BE, Irving SP, Aledort LM. Use of microcrystalline collagen for hemostasis after oral surgery in a hemophiliac. J Oral Surg 1979; 37: 126-128.
65. Vlachakis ND, Aledort L. Platelet aggregation in relationship to plasma catecholamines in patients with hypertension. Atherosclerosis 1979; 32: 451-460.
66. Aledort LM. Heparin Dosage: Is It Disease Specific? Prim Cardiol 1979; 5: 8-10.
67. Aledort LM. Comprehensive Care of Hemophilia. SE Asian J Trop Med Publ Health 1979; 10: 2: 280-281.
68. Aledort LM. Problem of Abnormal Hemostasis in Liver Disease. SE Asian J Trop Med Publ Health 1979; 10: 3: 348-349.
69. Aledort LM. At Last - A National Blood Policy? Hospital Practice 1979; 14: 11-15.
70. Hearings before the Subcommittee on Health of the Committee on Ways and Means, House of Representatives, Ninety-Sixth Congress, First Session, June 18, 27, 1979 (Amendments to the Medicare Program) (Testimony of Louis M. Aledort, MD) 1979, 200-204.
71. Vlachakis ND, Aledort L. Platelet Lipid Peroxides as Determinant of Platelet Survival and Sympathetic Stimulation in Patients with Hypertension. Biochem Med 1979; 21: 94-103.



72. Kasper CK, and the Hemophilia Study Group. Effect of Prothrombin Complex Concentrates on Factor VIII Inhibitor Levels. *Blood* 1979; 54: 6: 1358-1368.
73. Vlachakis ND, Aledort L. Hypertension and Propranolol Therapy: Effect on Blood Pressure, Plasma Catecholamines and Platelet Aggregation. *Am J Cardiol* 1980; 45: 321-325.
74. Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt PM, and the Hemophilia Study Group. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII. *N Engl J Med* 1980; 303: 8: 421-425.
75. Persantine-Aspirin Reinfarction Study Research Group, The. Persantine and Aspirin in Coronary Heart Disease. *Circulation* 1980; 62: 3: 449-461.
76. Aledort LM: Working together: the secret to financial counseling in hemophilia (interview). *ECHO* 1980; 1: 5: 2-3.
77. Persantine-Aspirin Reinfarction Study Research Group. Persantine-Aspirin Reinfarction Study: Design, Methods and Baseline Results. *Circulation* 1980; 62; 3: II1-42.
78. Aledort LM. The Availability of Plasma Products and the Care of Hemophilia Patients. *JAMA* 1981; 246: 2: 157.
79. Aledort LM. Introducing a New Series on Coagulation. *Prim Cardiol* 1981; 7: 11.
80. Aledort LM. Valvular Disease, Surgery, and Anticoagulation. *Prim Cardiol* 1981; 7: 10.
81. Aledort LM. Financing the Cost of Concentrates: The United States Experience. *Haemostasis* 1981; 10(suppl.1): 69-71.
82. Aledort LM. Lessons from hemophilia. *N Engl J Med* 1982; 306: 607-608.
83. Aledort LM. Principles of Anticoagulant Therapy: Guidelines for Prophylactic and Therapeutic Use. *Recognition and Mgmt of Thromboemb Disorders* 1982; 48-53.
84. Aledort LM. Letter to the editor. *N Engl J Med* 1982; 307: 556.
85. Aledort LM, Gorlin R. The Persantine-Aspirin Reinfarction Study. *Prim Cardiol* 1982; 8: 104-105.
86. Aledort LM. Effective Use of Anticoagulants. *Drug Therapy* 1982; 12: 107-117
87. Cederbaum AI, Blatt PM, Levine PH, and the Hemophilia Study Group. Abnormal Serum Transaminase Levels in Patients with Hemophilia A. *Arch Intern Med* 1982; 142: 481-484.
88. Aledort LM. Coagulation and Bleeding: The Physiologic Janus. *Hosp Prac* 1982; 17: 13-16.
89. Aledort LM. Current Concepts in Diagnosis and Management of Hemophilia. *Hosp Prac* 1982; 17: 77-92.
90. Hilgartner MW, Knatterud GL, and the FEIBA Study Group. The Use of Factor Eight Inhibitor By-Passing Activity (FEIBA Immuno) Product for Treatment of Bleeding Episodes in Hemophiliacs with Inhibitors. *Blood* 1983; 61: 1: 36-40.
91. Radensky PW, Sorett E, Schoenbaum EE, Aledort LM. Uncerative Colitis and Hemophilia A. *Mt. Sinai J Med* 1983; 50: 3: 268-269.



92. Aledort LM, Goodnight SH, Rao AV, Schwarz J, Whitehurst D, Shapiro SS, and Hemophilia Study Group. Impact of factor VIII deficiency on clotting factor utilization in the United States. *La Ricerca Clin Lab* 1983; 13: 33-41.
93. Aledort LM. A.I.D.S.: A 20th-Century Plague. *Prim Cardiol* 1983; 9: 15.
94. Aledort LM. What is the Prospective Impact of the Recombinant DNA Technique on the Production of Human Plasma Derivatives? Which are the Derivates Where Donor Plasma Could be Replaced? *Vox Sang* 1983; 44: 390-395.
95. Lusher JM, Blatt PM, Penner JA, Aledort LM, Levine PH, White GC, Warrier AI, Whitehurst DA. Autoplex Versus Proplex: A Controlled, Double-Blind Study of Effectiveness in Acute Hemarthroses in Hemophiliacs With Inhibitors to Factor VIII. *Blood* 1983; 62: 5: 1135-1138.
96. Aledort LM. The Bleeding Patient: A Systematic Approach to the Workup. *Diagnosis* 1984; 6: 87-90.
97. Smith PS, Levine PH, and the Directors of Eleven Participating Hemophilia Centers. The Benefits of Comprehensive Care of Hemophilia: A Five-Year Study of Outcomes. *Am J Pub Health* 1984; 74: 6: 616-617.
98. Aledort LM. Alternatives to Financing. *Scand J Haematol* 1984; 33(suppl 40): 455-457.
99. Aledort LM. Side Effects of Substitution Therapy. *Scand J Haematol* 1984; 33(suppl 40): 331-333.
100. Isola L, Forster A, Aledort LM. Desamino-D-Arginine Vasopressin and Bleeding Time in von Willebrand's Disease. *Ann Intern Med (letter)* 1984; 101: 5: 719-720.
101. Aledort LM. The Eye and the Organism. *Hosp Prac* 1984; 19: 14-15.
102. Aledort LM, Levine PH, Hilgartner M, Blatt P, Spero JA, Goldberg JD, Bianchi L, Desmet V, Scheuer P, Popper H, Berk PD. A Study of Liver Biopsies and Liver Disease Among Hemophiliacs. *Blood* 1985; 66: 2: 367-372.
103. Hilgartner MW, Aledort LM. AIDS in Hemophilia. *Ann NY Acad Sci* 1985; 437: 466-471.
104. Aledort LM, Gorlin R. Unexpected Recurrent Bleeding in Patient with Bjork-Shiley Prosthesis on Anticoagulants. *Prim Cardiol* 1985; 11: 156-161.
105. Jason J, Hilgartner M, Holman RC, Dixon G, Spira TJ, Aledort L, Evatt B. Immune Status of Blood Product Recipients. *JAMA* 1985; 253: 8: 1140-1145.
106. Johnson RE, Lawrence DN, Evatt BL, Bregman DJ, Zyla LD, Curran JW, Aledort LM, Eyster ME, Brownstein AP, Carman CJ. Acquired Immunodeficiency Syndrome among patients attending hemophilia treatment centers and mortality experience of hemophiliacs in the United States. *Am J Epidemiol* 1985; 121: 6: 797-810.
107. Jason J, McDougal JS, Holman RC, Stein SF, Lawrence DN, Nicholson JKA, Dixon G, Doxey M, Evatt BL, and the Hemophilia/AIDS Collaborative Study Group. Human T-Lymphotropic Retrovirus Type III / Lymphadenopathy-Associated Virus Antibody. *JAMA* 1985; 253: 23: 3409-3415.
108. Eyster ME, Whitehurst DA, Catalano PM, McMillan CW, Goodnight SH, Kasper CK, Gill JC, Aledort LM, Hilgartner MW, Levine PH, Edson JR, Hathaway WE, Lusher JM, Gill FM, Poole



- WK, Shapiro SS. Long-Term Follow-Up of Hemophiliacs with Lymphocytopenia or Thrombocytopenia. *Blood* 1985; 66: 6: 1317-1320.
109. Aledort LM. The Current Status of Transfusion Therapy. *AIDS Center News* 1985; 2: 4: 1-2.
  110. Markova I, Forbes CD, Aledort LM, Inwood M, Mandalaki T, Miller CH, Pittadaki J. A Comparison of the Availability and Content of Genetic Counseling as Perceived by Hemophilic men and Carriers in the U.S.A., Canada, Scotland and Greece. *Am J Med Genet* 1986; 24: 7-21.
  111. Jason JM, McDougal JS, Dixon G, Lawrence DN, Kennedy MS, Hilgartner M, Aledort L, Evatt BL. HTLV-III / LAV Antibody and Immune Status of Household Contacts and Sexual Partners of Persons with Hemophilia. *JAMA* 1986; 255: 2: 212-215.
  112. Klimt CR, Knatterud GL, Stamler J, Meier P, and the PARIS II Research Group. Persantine-Aspirin Reinfarction Study. Part II. Secondary Coronary Prevention With Persantine and Aspirin. *JACC* 1986; 7: 2: 251-269.
  113. Miller CH, Hilgartner MW, Harris MB, Bussel JB, Aledort LM. Concurrence of von Willebrand's Disease and Hemophilia A: Implications for Carrier Detection and Relevance. *Am J Med Genet* 1986; 24: 83-94.
  114. Fruchtman S, Aledort LM. Disseminated Intravascular Coagulation. *JACC* 1986; 8: 6: 159B-167B.
  115. O'Grady JG, Langley PG, Isola LM, Aledort LM, Williams R. Coagulopathy of Fulminant Hepatic Failure. *Sem Liver Dis* 1986; 6: 2: 159-163.
  116. Driscoll MC, Miller CH, Goldberg JD, Aledort LM, Hoyer, LW, Golbus, MS. Recombination Between Factor VIII: C Gene and St14 Locus. *Lancet* (letter) 1986; 2: 279.
  - 116A. Miller CH, Hilgartner MW, Aledort LM. Reproductive Choices in Hemophilic Men and Carriers. *Am J Med Genet* 1987; 26: 591-598.
  117. Kerr LD, Spiera H, Aledort LN (sic). Acute disseminated intravascular coagulation as a complication of systemic lupus erythematosus. *NYS J Med* 1987; 87: 181-183.
  118. Aledort LM. Factor VIII/ von Willebrand Factor Replacement Therapy. *Ann NY Acad Sci* 1987; 509: 49-52.
  119. Perkins HA, Cordell R, Bueno C, Shiota J, Hitchcock B. Progressive decrease in proportion of blood donors with antibody to HIV. *Transfusion* 1987; 27: 502.
  120. Miller CH, Aledort LM. Discriminant analysis for probability of hemophilia A carriership. *Blood* (editorial) 1985; 69: 704-705.
  121. Carnelli V, Gomperts ED, Friedman A, Aledort L, Hilgartner M, Dietrich S, Fedor EJ. Assessment for evidence of a Non A-Non B hepatitis in patients given n-heptane-suspended heat-treated clotting factor concentrates. *Thromb Res* 1987; 46: 827-834.
  122. Niland-Weiss J, Azen SP, Odom-Maryon T, Lui F, Hagerty C, and The Transfusion Safety Study Group. A Microcomputer-Based Distributed Data Management System for a Large Cooperative Study of Transfusion Associated Acquired Immunodeficiency Syndrome. *Comp Biomed Res* 1987; 20: 225-243.



123. Wallace EZ, Aledort LM, Levere R, Mushlin AI. A response to the recommendations of the New York State Commission on Graduate Medical Education concerning teaching in ambulatory care settings. *NYS J Med* 1987; 87: 11: 613-614.
124. Bianchi L, Desmet VJ, Popper H, Scheuer PJ, Aledort LM, Berk PD. Histologic Patterns of Liver Disease in Hemophiliacs, with Special Reference to Morphologic Characteristics of Non-A, Non-B Hepatitis. *Semin Liver Dis* 1987; 7: 3: 203-209.
125. Fletcher MA, Ashman MR, Baron GC. The Use of Whole Blood Methods in Assessment of Immune Parameters in Immuno-Deficiency States. *Diagn Clin Immunol* 1987; 5: 69-81.
126. McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J, and the Hemophilia Study Group. The Natural History of Factor VIII:C Inhibitors in Patients With Hemophilia A: A National Cooperative Study. II. Observations on the Initial Development of Factor VIII:C Inhibitors. *Blood* 1988; 71: 2: 344-348.
127. Driscoll MC, Dispenzieri A, Tobias E, Miller CH, Aledort LM. A Second BamHI DNA Polymorphism and Haplotype Association in the Factor IX Gene. *Blood* 1988; 72: 1: 61-65.
128. Wallace EZ, Aledort LM, Levere R, Mushlin AI. Teaching in Ambulatory Care Settings. *NYS J Med* (reply) 1988; 88: 155-156.
129. Aledort LM. Blood Products and Immune Changes: Impacts Without HIV Infection. *Semin Hematol* 1988; 25: 2(suppl): 14-24.
130. Aledort LM, Lipton RA, Hilgartner M. A Consortium for Purchase of Blood Products Directed by Physicians. *Ann Intern Med* 1988; 108: 5: 754-756.
131. Aledort LM, Hilgartner M, Lipton RA. Hemophilia - a treatment in crisis. *N Engl J Med* 1988; 319: 15: 1017.
132. Bussel JB, Pham LC, Aledort L, Nachman R. Maintenance Treatment of Adults With Chronic Refractory Immune Thrombocytopenic Purpura Using Repeated Intravenous Infusions of Gammaglobulin. *Blood* 1988; 72: 1: 121-127.
133. Aledort LM. Cryoprecipitate revisited. *Transfusion* (editorial) 1988; 28: 4: 295-296.
134. Gjerset G, Vyas GN, Bhat R, Operskalski EA, and the Transfusion Safety Study Group. Phenotypes for Group-Specific Component Among Patients Exposed to Human Immunodeficiency Virus by Transfusions. *J Infect Dis* 1988; 157: 3: 609-610.
135. Govindarajan S, Edwards VM, Stuart ML, Operskalski EA, Mosley JW, and the Transfusion Safety Study Group. Influence of Human Immunodeficiency Virus Infection on Expression of Chronic Hepatitis B and D Virus Infections. *Viral Hep Liv Dis* 1988; 201-204.
136. Kaplan J, Sarnaik I, Lusher J, and the Transfusion Safety Study Group. Increase in Leu 2<sup>+</sup> Leu 7<sup>+</sup> Lymphocytes in HIV 1-Seropositive Patients with Hemophilia Repeatedly Treated With Clotting Factor Concentrates. *Clin Immunol Immunopath* 1988; 46: 337-341.
137. Aledort LM. Risks Associated With Homologous Blood Transfusion. *J Cardiothor Anesth* 1988; 2: 6(suppl): 2-6.
138. Bishop PC, Boone D, Parker JW. Immunophenotypes by Flow Cytometry: A Longitudinal Study in Healthy Individuals. *Diagn Clin Immunol* 1988; 5: 232-240.



139. Brown NA, Kovacs A, Lui CR, Hur C, Zaia JA, Mosley JW. Prevalence of antibody to Human Herpesvirus 6 among blood donors infected with HIV. *Lancet* 1988; 2: 1146.
- 139A. Lawrence DN, Jason JM, Holman RC, Heine P, Evatt BL, and the Hemophilia Study Group. Sex Practices Correlates of Human Immunodeficiency Virus Transmission and Acquired Immunodeficiency Syndrome Incidence in Heterosexual Partners and Offspring of U.S. Heterosexual Men. *Am J Hematol* 1989; 30: 68-76.
140. Norman GL, Barker SS, Rasheed S, and the Transfusion Safety Study Group. Immunoblot Reactivity of a Non-HIV Protein With Human Sera. *J Clin Lab Anal* 1989; 3: 148-151.
141. Uehlinger J, Rose E, Aledort LM. Successful treatment of an acquired von Willebrand factor antibody by extracorporeal immunoadsorption. *N Engl J Med* 1989; 320: 4: 254-255.
142. Aledort LM. New Approaches to Management of Bleeding Disorders. *Hosp Prac* 1989; 24: 2: 207-226.
143. Edwards VM, Mosley JW, and the Transfusion Safety Study Group. Reproducibility in Quality Control of Protein (Western) Immunoblot Assay for Antibodies to Human Immunodeficiency Virus. *Am J Clin Pathol* 1989; 91: 1: 75-78.
144. Goedert JJ, Kessler CM, Aledort LM, Biggar RJ, Andes WA, White II GC, Drummond JE, Vaidya K, Mann DL, Eyster ME, Ragni MV, Lederman MM, Cohen AR, Bray GL, Rosenberg PS, Friedman RM, Hilgartner MW, Blattner WA, Kroner B, Gail MH. A prospective study of Human Immunodeficiency Virus Type 1 Infection and the development of AIDS in subjects with Hemophilia. *N Engl J Med* 1989; 321: 17: 1141-1148.
145. Antman KH, Aledort LM, Yarbrow J, Wilensky G, Wojcik S, Monaco GP, Windham S. Cost-effectiveness and Reimbursement in Patient Care. *Semin Hematol* 1989; 26: 3(suppl): 32-45.
146. Driscoll MC, Bouhassira E, Aledort LM. A Codon 338 Nonsense Mutation in the Factor IX Gene in Unrelated Hemophilia B Patients: Factor IX<sup>338</sup> New York. *Blood* 1989; 74: 2: 737-742.
147. Fletcher MA, Azen SP, Adelsberg B, Gierset G, Hassett J, Kaplan J, Niland JC, Odom-Maryon T, Parker JW, Stites DP, Mosley JW, and the Transfusion Safety Study Group. Immunophenotyping in a Multicenter Study: The Transfusion Safety Study Experience. *Clin Immunol Immunopath* 1989; 52: 38-47.
148. Aledort LM, Essig B. AIDS Laws - Impractical Solutions to Practical Problems. *Hosp Prac* 1989 July; 11-12.
149. McClure E, Gaynor S, Veiga-Benach A, O'Neil D, and the Transfusion Safety Study Group. Notification of Recipients of Human Immunodeficiency Virus (HIV) Antibody Positive Transfusions. *Nursing* 1989; January: 10.
150. Mosley JW, Nowicki M, Kleinman SH, Dietrich SL, and the Transfusion Safety Study Group. Reactivation of Hepatitis B. *Lancet* 1989; 1: 1083-1084.
151. Kleinman SH, Niland JC, Azen SP, Operskalski EA, Barbosa LH, Chernoff AI, Edwards VM, Lenes BA, Marshall GJ, Nemo GJ, Norman GL, Perkins NH, Pindyck J, Pitlick F, Rasheed S, Shriver K, Toy P, Tomasulo PA, Waldman A, Mosley JW, and the Transfusion Safety Study Group. Prevalence of antibodies to Human Immunodeficiency Virus Type 1 among blood donors prior to screening. *Transfusion* 1989; 29: 7: 572-580.
152. Operskalski EA, Schiff ER, Kleinman SH, Busch M, Taylor PE, Parks WP, Lee H, Tomasulo PA,



- Tomasulo PA, Donegan E, Stuart M, Hollingsworth CG, Nemo GJ, Mosley JW, and the Transfusion Safety Study Group. Epidemiologic background of blood donors with antibody to human T-cell lymphotropic virus. *Transfusion* 1989; 29: 8: 746-748.
153. Lang DJ, Kovacs AAS, Zaia JA, Doelkin G, Niland JC, Aledort L, Azen SP, Fletcher MA, Gauderman J, Gjerset GJ, Lusher J, Operskalski EA, Parker JW, Pegelow C, Vyas GN, Mosley JW, and the Transfusion Safety Study Group. Seroepidemiologic Studies of Cytomegalovirus and Epstein-Barr Virus Infections in Relation to Human Immunodeficiency Virus Type 1 Infection in Selected Recipient Populations. *J Acq Imm Def Syndr* 1989; 2: 540-549.
  154. Uehlinger J, Aledort LM. Blood-Product Usage in Cardiac Surgery. *J Cardiothor Anesth* 1989; 3: 6: 776-784.
  155. Brettler DB, Forsberg AD, Levine PH, Aledort LM, Hilgartner MW, Kasper CK, Lusher JM, McMillan C, Roberts H, and the Cooperating Investigators. The Use of Porcine Factor VIII Concentrate (Hyate:C) in the Treatment of Patients With Inhibitor Antibodies to Factor VIII. *Arch Intern Med* 1989; 149: 1381-1385.
  156. Jason J, Ou CY, Moore JL, Lawrence DN, Schochetman G, Evatt BL. Prevalence of Human Immunodeficiency Virus Type 1 DNAP in Hemophilic Men and Their Sex Partners. *J Infect Dis* 1989; 160: 789-794.
  157. Rose E, Forster A, Aledort LM. Correction of prolonged bleeding time in von Willebrand's disease with Humate-P. *Transfusion* 1990; 30: 4: 381.
  158. Parker JW, Adelsberg B, Boone D, and the Transfusion Safety Study Group. Leukocyte Immunophenotyping of Recipients of Blood and Blood Products. A Multisite Flow Cytometry study: Approach to Organization, Standardization, Quality Control, and Date Management. *Clin Immunol Immunopath* 1990; 55: 187-220.
  159. Busch MP, Donegan E, Stuart M, Mosley JW, and the Transfusion Safety Study Group: Donor HIV-1 p24 Antigenemia and Course of Infection in Recipients. *Lancet* 1990; 1: 1342.
  160. Hilgartner M, Aledort L, Andes A, Gill J, and the members of the FEIBA Study Group. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. *Transfusion* 1990; 30: 626-630.
  - 160A. Lipton RA, Aledort LM, Hilgartner M. The physician-directed blood product purchasing consortium during a worldwide shortage of factor VIII concentrate. *Transfusion* 1990; 30: 6: 573.
  161. Uehlinger J, Button GR, McCarthy J, Forster A, Watt R, Aledort LM. Immunoabsorption for coagulation factor inhibitors. *Transfusion* 1991; 31: 3: 265-269.
  162. Donegan E, Busch MP, Galleshaw JA, Shaw GM, Mosley JW, and the Transfusion Safety Study Group. Transfusion of Blood Components from a Donor with Human T-Lymphotropic Virus Type II (HTLV-II) Infection. *Ann Intern Med* 1990; 113: 555-556.
  163. Dietrich SL, Mosley JW, Lusher JM, Hilgartner MW, Operskalski EA, Habel L, Aledort LM, Gjerset GF, Koerper MA, Lewis BH, Pegelow CH, and the Transfusion Safety Study Group. Transmission of Human Immunodeficiency Virus Type 1 by Dry-Heated Clotting Factor Concentrates. *Vox Sang* 1990; 59: 129-135.
  164. Donegan E, Stuart M, Niland JC, Sacks HS, Azen SP, Dietrich SL, Faucett C, Fletcher MA, Hagerty C, Kleinman SH, Operskalski EA, Perkins H, Pindyck J, Schiff ER, Stites D, Tomasulo PA, Mosely JW, and the Transfusion Safety Study Group. Infection with Human